Adial Pharmaceuticals Inc. - notizie pubblicate 178 - letture 4.525
ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Adial pharmaceuticals reports second quarter 2024 financial results and provides business update glen allen, va., aug. 14, 2024 (globe newswire) --adial pharmaceuticals, inc. (nasd ...
ADIAL PHARMACEUTICALS INC.
Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)
United states securities and exchange commission washington, d.c. 20549 form 10-q ☒quarterly report pursuant to section 13 or 15(d) of the securities exchange act of 1934 for the ...
ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04
Glen allen, va., aug. 13, 2024 - adial pharmaceuticals, inc. (nasdaq: adil) ("adial" or the "company"), a clinical-stage biopharmaceutical company focused on de ...
ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of ad04 topline results expected during the fourth quarter glen allen, va., aug. 07, 2024 ...
ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer adial pharmaceutical ...
ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Glen allen, va., july 23, 2024 - adial pharmaceuticals, inc. (nasdaq: adil) ("adial" or the "company"), a clinical-stage biopharmaceutical company focused on de ...
ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
Adial pharmaceuticals announces publication in leading peer-reviewed journal supporting the potential efficacy of ad04 as a precision medicine for the treatment of alcohol use diso ...
ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial pharmaceuticals achieves important milestone of first patient dosed in pharmacokinetics study of ad04 for the treatment of alcohol use disorder study intended to optimize des ...
ADIAL PHARMACEUTICALS INC.
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
Glen allen, va., may 29, 2024 - adial pharmaceuticals, inc. (nasdaq: adil) ("adial" or the "company"), a clinical-stage biopharmaceutical company focused on dev ...
ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Adial pharmaceuticals reports first quarter 2024 financial results and provides business update glen allen, va., may 15, 2024 (globe newswire) --adial pharmaceuticals, inc. (nasdaq ...
ADIAL PHARMACEUTICALS INC.
Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)
United states securities and exchange commission washington, d.c. 20549 form 10-q ☒quarterly report pursuant to section 13 or 15(d) of the securities exchange act of 1934 for the ...
ADIAL PHARMACEUTICALS INC.
Supplemental Prospectus - Form 424B3
Filed pursuant to rule 424(b)(3) prospectus registration no. 333-278652 2,369,000 shares of common stock this prospectus relates to the resale from time to time of up to an aggrega ...
ADIAL PHARMACEUTICALS INC.
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
Adial pharmaceuticals granted key patent from the united states patent and trademark office glen allen, va., april 22, 2024 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: ...
ADIAL PHARMACEUTICALS INC.
Notice of Effectiveness - Form EFFECT
Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: april 19, 2024 5:00 p.m. form: s-3 cik: ...
ADIAL PHARMACEUTICALS INC.
Supplemental Prospectus - Form 424B5
Filed pursuant to rule 424(b)(5) registration no. 333-276496 prospectus supplement (to prospectus dated january 24, 2024) adial pharmaceuticals, inc. up to $4,283,650 shares of com ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti